Study of investigational drugs with ERAS-801 for glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests two new investigational drugs (ABBV-637, ABBV-155) combined with another drug (ERAS-801) for people with glioblastoma. The goal is to see if this combination can shrink the tumor or slow its growth. You need to have a specific genetic marker (EGFR amplification) in your tumor to be eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of brain cancer called glioblastoma (WHO grade IV).
- Your tumor must have a specific genetic change called EGFR amplification.
- You must be healthy enough to undergo surgery to remove part of the tumor (at least 500 mg of tissue).
- You must have had no more than 2 prior cancer treatments.
- You must have recovered from side effects of previous treatments (e.g., at least 12 weeks after radiation, 3 weeks after chemotherapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called ERAS-801 for people with a type of brain cancer called glioblastoma or gliosarcoma that has a specific genetic change (EGFR amplification or mutation). The study has two groups: one for people whose tumor has come back after treatment, and another for older adults (70+) who are newly diagnosed. The drug targets the EGFR pathway, which may help slow tumor growth.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial offers expanded access to an experimental treatment (RZ-001) for people with recurrent glioblastoma (a type of brain cancer) that has grown again after initial treatment. It is for those who cannot join other clinical trials and aims to provide possible treatment options when standard ones have failed.
This trial tests whether adding the study drug azeliragon to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma. The study will also look at how the tumor responds to the added drug.
This trial tests combining an immunotherapy drug (adebrelimab) with the standard chemotherapy temozolomide, with or without hyperbaric oxygen treatment, for patients with newly diagnosed glioblastoma who have already completed standard radiation and chemotherapy. The goal is to see if this combination can improve outcomes.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.